Another study showed that targeting DDR1 with a humanized monoclonal antibody reversed immune exclusion by increasing T-cell infiltration and significantly increased antitumor efficacy in a mouse model of immunocompetent breast cancer [18]. This evidence concerns the gene DDR1 and breast cancer.